U3 Pharma AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From U3 Pharma AG
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Daiichi Sankyo Co., Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.